telmisartan has been researched along with Bone Loss, Osteoclastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, LJ; Ji, H; Ji, JL; Li, YQ; Liu, K; Ma, L; Yu, X | 1 |
| Ganburged, G; Moriyama, K; Suda, N | 1 |
2 other study(ies) available for telmisartan and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biomarkers; Biomechanical Phenomena; Blood Pressure; Body Weight; Bone Density; Bone Remodeling; Bone Resorption; Female; Heart Rate; Lumbar Vertebrae; Ovariectomy; Rats; Rats, Inbred SHR; Rosiglitazone; Systole; Telmisartan; Thiazolidinediones; Tibia; Time Factors; X-Ray Microtomography | 2010 |
Effect of angiotensin II receptor blocker on experimental periodontitis in a mouse model of Marfan syndrome.
Topics: Alveolar Bone Loss; Angiotensin Receptor Antagonists; Animals; Bacteroidaceae Infections; Benzimidazoles; Benzoates; Bone Resorption; Disease Models, Animal; Inflammation; Interleukin-17; Male; Marfan Syndrome; Mice; Osteoclasts; Periodontitis; Porphyromonas gingivalis; Telmisartan; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2013 |